Effectiveness of Short-Term Use Denosumab and Risedronate Using β-Crosslaps and Histopathology as a Parameter in Osteoporotic Rat Model
Osteoporosis is a condition of decreased bone mass density. Pharmacological management uses drugs that decrease bone resorption or increase bone formation. The most commonly used drugs are bisphosphonates. Risedronate is one of these bisphosphonates. It inhibits osteoclasts, resulting in osteoclast...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Padjajaran
2024-09-01
|
| Series: | Majalah Kedokteran Bandung |
| Subjects: | |
| Online Access: | https://journal.fk.unpad.ac.id/index.php/mkb/article/view/3016 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850065835377295360 |
|---|---|
| author | Afrisya Bimo Siwendro Ahmad Ramdan Yoyos Dias Ismiarto Anglita Yantisetiasti Dliyauddin fachri |
| author_facet | Afrisya Bimo Siwendro Ahmad Ramdan Yoyos Dias Ismiarto Anglita Yantisetiasti Dliyauddin fachri |
| author_sort | Afrisya Bimo Siwendro |
| collection | DOAJ |
| description | Osteoporosis is a condition of decreased bone mass density. Pharmacological management uses drugs that decrease bone resorption or increase bone formation. The most commonly used drugs are bisphosphonates. Risedronate is one of these bisphosphonates. It inhibits osteoclasts, resulting in osteoclast apoptosis. Denosumab is a human monoclonal antibody that inhibits receptor activator kappa-B ligand, inhibiting osteoclast activation. Both drugs are widely used. Research on the efficacy of these two mechanisms has yet to obtain conclusive results. β-cross-laps is a parameter that can be used to evaluate the effectiveness of therapy through monitoring the bone resorption process. This experimental study used female rats >9 weeks old and was conducted at the Pharmacology and Therapeutic Laboratory, Universitas Padjadjaran Bandung, Indonesia, from June to September 2021. This study utilized a simple random sampling to allocate 24 experimental animals into three groups: control, risedronate, and denosumab. β-Crosslaps expression values before ovariectomy, post ovariectomy before receiving medication, and post ovariectomy and receiving medication was recorded and statistically analyzed using the SPSS version 24.0. The analysis of 24 samples revealed a statistically significant decrease in the median value of β-Crosslaps after ovariectomy in the denosumab group (p=0.036) when compared to the control group, whereas the decrease in the risedronate group was not significant (p=0.687). Administration of denosumab in rat models is more effective in reducing bone resorption compared to risedronate. |
| format | Article |
| id | doaj-art-ebc60b8a4e114663a35aadc544ca5bce |
| institution | DOAJ |
| issn | 0126-074X 2338-6223 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Universitas Padjajaran |
| record_format | Article |
| series | Majalah Kedokteran Bandung |
| spelling | doaj-art-ebc60b8a4e114663a35aadc544ca5bce2025-08-20T02:48:54ZengUniversitas PadjajaranMajalah Kedokteran Bandung0126-074X2338-62232024-09-0156319720210.15395/mkb.v56.30161754Effectiveness of Short-Term Use Denosumab and Risedronate Using β-Crosslaps and Histopathology as a Parameter in Osteoporotic Rat ModelAfrisya Bimo Siwendro0Ahmad Ramdan1Yoyos Dias Ismiarto2Anglita Yantisetiasti3Dliyauddin fachri4Department of Orthopaedic and Traumatology, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital BandungDepartment of Orthopaedic and Traumatology, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital BandungDepartment of Orthopaedic and Traumatology, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital BandungDepartment of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital BandungDepartment of Orthopaedic and Traumatology, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital BandungOsteoporosis is a condition of decreased bone mass density. Pharmacological management uses drugs that decrease bone resorption or increase bone formation. The most commonly used drugs are bisphosphonates. Risedronate is one of these bisphosphonates. It inhibits osteoclasts, resulting in osteoclast apoptosis. Denosumab is a human monoclonal antibody that inhibits receptor activator kappa-B ligand, inhibiting osteoclast activation. Both drugs are widely used. Research on the efficacy of these two mechanisms has yet to obtain conclusive results. β-cross-laps is a parameter that can be used to evaluate the effectiveness of therapy through monitoring the bone resorption process. This experimental study used female rats >9 weeks old and was conducted at the Pharmacology and Therapeutic Laboratory, Universitas Padjadjaran Bandung, Indonesia, from June to September 2021. This study utilized a simple random sampling to allocate 24 experimental animals into three groups: control, risedronate, and denosumab. β-Crosslaps expression values before ovariectomy, post ovariectomy before receiving medication, and post ovariectomy and receiving medication was recorded and statistically analyzed using the SPSS version 24.0. The analysis of 24 samples revealed a statistically significant decrease in the median value of β-Crosslaps after ovariectomy in the denosumab group (p=0.036) when compared to the control group, whereas the decrease in the risedronate group was not significant (p=0.687). Administration of denosumab in rat models is more effective in reducing bone resorption compared to risedronate.https://journal.fk.unpad.ac.id/index.php/mkb/article/view/3016β-cross-laps, denosumab, risedronate, osteoporosis |
| spellingShingle | Afrisya Bimo Siwendro Ahmad Ramdan Yoyos Dias Ismiarto Anglita Yantisetiasti Dliyauddin fachri Effectiveness of Short-Term Use Denosumab and Risedronate Using β-Crosslaps and Histopathology as a Parameter in Osteoporotic Rat Model Majalah Kedokteran Bandung β-cross-laps, denosumab, risedronate, osteoporosis |
| title | Effectiveness of Short-Term Use Denosumab and Risedronate Using β-Crosslaps and Histopathology as a Parameter in Osteoporotic Rat Model |
| title_full | Effectiveness of Short-Term Use Denosumab and Risedronate Using β-Crosslaps and Histopathology as a Parameter in Osteoporotic Rat Model |
| title_fullStr | Effectiveness of Short-Term Use Denosumab and Risedronate Using β-Crosslaps and Histopathology as a Parameter in Osteoporotic Rat Model |
| title_full_unstemmed | Effectiveness of Short-Term Use Denosumab and Risedronate Using β-Crosslaps and Histopathology as a Parameter in Osteoporotic Rat Model |
| title_short | Effectiveness of Short-Term Use Denosumab and Risedronate Using β-Crosslaps and Histopathology as a Parameter in Osteoporotic Rat Model |
| title_sort | effectiveness of short term use denosumab and risedronate using β crosslaps and histopathology as a parameter in osteoporotic rat model |
| topic | β-cross-laps, denosumab, risedronate, osteoporosis |
| url | https://journal.fk.unpad.ac.id/index.php/mkb/article/view/3016 |
| work_keys_str_mv | AT afrisyabimosiwendro effectivenessofshorttermusedenosumabandrisedronateusingbcrosslapsandhistopathologyasaparameterinosteoporoticratmodel AT ahmadramdan effectivenessofshorttermusedenosumabandrisedronateusingbcrosslapsandhistopathologyasaparameterinosteoporoticratmodel AT yoyosdiasismiarto effectivenessofshorttermusedenosumabandrisedronateusingbcrosslapsandhistopathologyasaparameterinosteoporoticratmodel AT anglitayantisetiasti effectivenessofshorttermusedenosumabandrisedronateusingbcrosslapsandhistopathologyasaparameterinosteoporoticratmodel AT dliyauddinfachri effectivenessofshorttermusedenosumabandrisedronateusingbcrosslapsandhistopathologyasaparameterinosteoporoticratmodel |